loncastuximab tesirine · Medicine question

Which cancers is loncastuximab tesirine (Zynlonta) licensed to treat, and in which patients?

Name: Which cancers is loncastuximab tesirine (Zynlonta) licensed to treat, and in which patients?
Published: 2026-11-08T01:56:01.764Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Loncastuximab tesirine (Zynlonta) is licensed as monotherapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.

Sources for this answer

Zynlonta, 10mg, powder for concentrate for solution for infusionSwedish Orphan Biovitrum Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 6Document updated 23 February 2026

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about loncastuximab tesirine